82 search results for: patient burden

CRSwNP at Center Stage: Impact of Biologics in <b>Patient</b>s with Co-existing Type 2 Asthma
Pulmonology
CRSwNP at Center Stage: Impact of Biologics in Patients with Co-existing Type 2 Asthma
expert video

In this video soundbite from the EAACI 2025 symposium, Dr. Philippe Gevaert explains how biologic options for uncontrolled CRSwNP are increasing, and phase 3 studies of approved biologics show improved outcomes and decreased SCS use/surgery in patients with CRSwNP. Additionally, he explains how biologics targeting type 2 inflammatory pathophysiology potentially improve outcomes for eligible patients with co-existing CRSwNP and asthma.

View more
Type 2 Inflammatory Diseases Can Negatively Impact <b>Patient</b>s and Their Caregivers
Type 2 Inflammation
Type 2 Inflammatory Diseases Can Negatively Impact Patients and Their Caregivers
expert video

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof Oscar Palomares highlights the substantial impact of type 2 inflammatory diseases on the quality of life of patients and their caregivers.

View more
AANP 2025 | Atopic Diseases & a Case-Based Panel of Nurse Practitioners
Type 2 Inflammation
AANP 2025 | Atopic Diseases & a Case-Based Panel of Nurse Practitioners
videoanimation

Experts from different specialties use a case-based discussion to understand type 2 inflammatory diseases from a nurse practitioner perspective.

View more
The Potential Sequelae of Missed Opportunities: How Systemic Type 2 Inflammation Can Shape a <b>Patient</b>'s Life
Dermatology
The Potential Sequelae of Missed Opportunities: How Systemic Type 2 Inflammation Can Shape a Patient's Life
expert video

Dr. Nicole Chase describes a potential hypothesis for the link between the shift to an industrialized society and the rise in type 2 inflammatory diseases, highlighting the loss of immunomodulatory mechanisms driven by helminthic infections. She explains how unopposed immune responses to common environmental allergens may cause chronic type 2 inflammation, manifesting throughout the body.

View more
GUF PNG
On Demand
Translating the Science of CSU: From Pathogenesis to Patient Outcomes

Watch as Drs. Michihiro Hide, Marta Ferrrer, and Ana M. Giménez-Arnau discuss chronic spontaneous urticaria (CSU) and highlight the unmet needs, importance of disease control, and emerging therapies.

Managing Type 2 Inflammatory Diseases: Multidisciplinary Frame of Mind
Type 2 Inflammation
Managing Type 2 Inflammatory Diseases: Multidisciplinary Frame of Mind
expert video

Drs. Bob Geng and Lawrence Eichenfield highlight a multidisciplinary team approach to patient-centered care in diseases with type 2 inflammation

View more
Dynamic Eosinophils: Decoding Variability in COPD
Pulmonology
Dynamic Eosinophils: Decoding Variability in COPD
interactivity

Explore how blood eosinophil counts can fluctuate over time in patients with COPD and how repeat measurements may help reveal patterns of underlying type 2 inflammation.

View more
What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP
On Demand
What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP

The March 2025 ADVENT symposium in Orlando, Florida brought together 4 dermatology experts to explore the evolving science of type 2 inflammation. Type 2 inflammation plays a central role in the pathophysiology of multiple dermatological diseases, driving chronic immune dysregulation that affects patients with atopic dermatitis (AD) prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP). Understanding the mechanisms behind type 2 inflammation is key to advancing care and improving patient quality of life.

Eosinophils: A Biomarker in COPD
Pulmonology
Eosinophils: A Biomarker in COPD
Infographic

Learn how to identify chronic obstructive pulmonary disease (COPD) patients with type 2 inflammation using blood eosinophil (EOS) levels, understand the associated risks, and recognize factors that may influence EOS counts.

View more
IFOS 2023 | Type 2 Inflammation and Clinically Relevant Improvements in CRSwNP
On Demand
IFOS 2023 | Type 2 Inflammation and Clinically Relevant Improvements in CRSwNP

Dr. Stella Lee and Profs. Peter Hellings and Wytske Fokkens discuss type 2 inflammation, partnering with patients to improve outcomes, and real-world data on biologic effectiveness in CRSwNP.